Literature DB >> 33642096

Machine learning and augmented human intelligence use in histomorphology for haematolymphoid disorders.

Ahmad Nanaa1, Zeynettin Akkus2, Winston Y Lee3, Liron Pantanowitz3, Mohamed E Salama4.   

Abstract

Advances in digital pathology have allowed a number of opportunities such as decision support using artificial intelligence (AI). The application of AI to digital pathology data shows promise as an aid for pathologists in the diagnosis of haematological disorders. AI-based applications have embraced benign haematology, diagnosing leukaemia and lymphoma, as well as ancillary testing modalities including flow cytometry. In this review, we highlight the progress made to date in machine learning applications in haematopathology, summarise important studies in this field, and highlight key limitations. We further present our outlook on the future direction and trends for AI to support diagnostic decisions in haematopathology.
Copyright © 2021 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Machine learning; artificial intelligence; haematopathology; leukaemia; lymphoma

Year:  2021        PMID: 33642096     DOI: 10.1016/j.pathol.2020.12.004

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  2 in total

1.  Optimal Deep Transfer Learning-Based Human-Centric Biomedical Diagnosis for Acute Lymphoblastic Leukemia Detection.

Authors:  Manar Ahmed Hamza; Amani Abdulrahman Albraikan; Jaber S Alzahrani; Sami Dhahbi; Isra Al-Turaiki; Mesfer Al Duhayyim; Ishfaq Yaseen; Mohamed I Eldesouki
Journal:  Comput Intell Neurosci       Date:  2022-05-30

Review 2.  A Review of Artificial Intelligence Applications in Hematology Management: Current Practices and Future Prospects.

Authors:  Yousra El Alaoui; Adel Elomri; Marwa Qaraqe; Regina Padmanabhan; Ruba Yasin Taha; Halima El Omri; Abdelfatteh El Omri; Omar Aboumarzouk
Journal:  J Med Internet Res       Date:  2022-07-12       Impact factor: 7.076

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.